VKTX — Viking Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1607678 ·
Last close
$28.51
Market Cap
$3.33B
52W High
$43.15
52W Low
$25.77
ADV30
6,769,951
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -132,597,000 | -128,022,000 | 521,898,000 | 125,750,000 | — |
| Mar 2026 | 0 | — | -164,125,000 | -158,325,000 | 608,242,000 | 118,116,000 | 106,325,000 |
| Dec 2025 | 0 | — | -164,738,000 | -157,662,000 | 715,729,000 | 165,810,000 | 76,667,000 |
| Sep 2025 | 0 | — | -98,561,000 | -90,787,000 | 739,415,000 | 100,376,000 | 26,385,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-418,441,000
Investing CF
$399,257,000
Financing CF
$111,246,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.66
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,133,893,000
Inventory
—
Receivables
—
ST Investments
$375,913,000
EBIT TTM
$-560,021,000
Pretax Income TTM
$-534,796,000
Interest Exp TTM
—
Analysts
19
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -393,342,000 | -359,639,000 | 715,729,000 | 76,667,000 | 639,062,000 | -278,685,000 |
| Dec 2024 | 0 | -150,921,000 | -109,963,000 | 908,321,000 | 28,043,000 | 880,278,000 | -87,790,000 |
| Dec 2023 | 0 | -100,827,000 | -85,895,000 | 368,490,000 | 20,071,000 | 348,419,000 | -73,376,000 |
| Dec 2022 | 0 | -70,355,000 | -68,867,000 | 168,529,000 | 23,207,000 | 145,322,000 | -48,397,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-472,335,000
OpCashFlow TTM
—
Assets (Latest)
$608,242,000
Forward EPS
$-4.32
Max Pain — expiry 2026-10-16
max pain strike: $30.00 · spot: $28.51 · call oi: 69,054 · put oi: 26,022
Expected Move to 2026-10-16:
±$1.88
(6.58%) —
implied range
$26.64 –
$30.39
· ATM straddle on $28.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARQT | Arcutis Biotherapeutics, Inc. | $3.34B | $26.58 | — |
| PBLS | Parabilis Medicines, Inc. | $3.35B | $27.48 | — |
| ACAD | ACADIA PHARMACEUTICALS INC | $3.41B | $19.78 | — |
| IDYA | IDEAYA Biosciences, Inc. | $3.48B | $36.11 | — |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.14B | $28.14 | — |
News headlines (Yahoo Finance, 1h cache)
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
2026-10-09 20:45 · Yahoo
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know
2026-10-08 20:50 · Yahoo
Analyst Predicts 316% Upside for Viking Therapeutics Stock Despite 30%+ Loss in Last 3 Months
2026-10-08 17:09 · Yahoo
VKTX Down 16% in a Month: Time to Invest or Exit the Stock?
2026-10-06 12:13 · Yahoo
Does Viking Therapeutics (VKTX) Pairing VK2735 Data With Fresh Capital Signal A Sharpened Obesity Strategy?
2026-10-02 14:09 · Yahoo
Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?
2026-10-02 12:20 · Yahoo
Prediction: This Stock Could Double Over the Next 5 Years
2026-10-02 10:35 · Yahoo
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors
2026-10-01 20:45 · Yahoo
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
2026-09-30 21:20 · Yahoo
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts
2026-09-30 20:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.